NCT04937283 is a NA clinical trial of Segmentectomy in Lung Adenocarcinoma, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT04937283?

NCT04937283 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT04937283?

Interventions in NCT04937283: Segmentectomy, Lobectomy.

What condition does NCT04937283 study?

NCT04937283 studies Lung Adenocarcinoma.

Is NCT04937283 still recruiting?

NCT04937283 is currently recruiting now. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT04937283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Recruiting now NA Last updated 13 April 2026

What this trial tests

NA trial testing Segmentectomy in Lung Adenocarcinoma in 690 participants. Currently enrolling.

Timeline

1 October 2019

Primary endpoint
30 December 2028

30 December 2028

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	690
Start date	1 October 2019
Primary completion	30 December 2028
Estimated completion	30 December 2028
Sites	14 locations across China

Drugs / interventions tested

Segmentectomy
Lobectomy

Conditions studied

Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 20 to 79, any sex, with Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized controlled trials in lung cancer surgery: How are we doing?
Wong LY, Li Y, Elliott IA, Backhus LM, et al · · 2024 · cited 1× · PMID 38690441 · DOI 10.1016/j.xjon.2024.01.008
Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches.
Ohtaki Y, Aokage K, Miyoshi T, Tane K, et al · · 2026 · PMID 41642077 · DOI 10.1093/jjco/hyag013

Verify or expand the search:

Other trials of Segmentectomy

Trials testing the same drug.

NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06496659 — Segmentectomy After Induction Therapy (SAINT) · NA · recruiting
NCT06634966 — Segmentectomy for Solid-dominant Lung Cancer · Phase 3 · recruiting
NCT05717803 — Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) · Phase 3 · recruiting
NCT04944563 — Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field · NA · recruiting

Other recruiting trials for Lung Adenocarcinoma

Currently open trials in the same condition.

NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04937283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing